MedTrace Logo

Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)

NCT01069770 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2011-06-23

No results posted yet for this study

Summary

The purpose of this study is to see whether neoadjuvant administration of Sunitinib reduces the size of the primary kidney tumor in patients with metastatic disease undergoing cytoreductive surgery. The study will also assess the safety of neoadjuvant Sunitinib, objective response rate, respectability of primary tumor, quality of life, and survival advantages.

Conditions

Interventions

DRUG

Sunitinib

50mg daily(4 weeks on \& 2 weeks off), 2 cycles, until progression or unacceptable toxicity develops

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Korean Urological Oncology Society

    lead OTHER

Principal Investigators

  • Sungjoon Hong, M.D., Ph.D · The Korean Urological Oncology Society

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-12-31
Completion
2012-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01069770 on ClinicalTrials.gov